A new approach to immunosuppressive therapy in patients with glomerulonephritis with nephrotic syndrome

Glomerulonephritis (GN) is a group of immuno-inflammatory kidney diseases with predominant glomerular lesions that are difficult to treat. The greatest problems are caused by the treatment of GN with nephrotic syndrome, which often has a recurrent course. The aim of the research was to study the eff...

Full description

Bibliographic Details
Main Authors: S. I. Kudryashov, M. A. Stenina, L. M. Karzakova, T. S. Lutkova
Format: Article
Language:Russian
Published: St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists 2024-01-01
Series:Медицинская иммунология
Subjects:
Online Access:https://www.mimmun.ru/mimmun/article/view/2670
_version_ 1797197764102193152
author S. I. Kudryashov
M. A. Stenina
L. M. Karzakova
T. S. Lutkova
author_facet S. I. Kudryashov
M. A. Stenina
L. M. Karzakova
T. S. Lutkova
author_sort S. I. Kudryashov
collection DOAJ
description Glomerulonephritis (GN) is a group of immuno-inflammatory kidney diseases with predominant glomerular lesions that are difficult to treat. The greatest problems are caused by the treatment of GN with nephrotic syndrome, which often has a recurrent course. The aim of the research was to study the effectiveness of recombinant interleukin-2 (rIL-2) therapy in the GN patients with nephrotic syndrome. 62 patients with a nephrotic form of primary GN with frequent relapses admitted to the Nephrology Department have been recruited into the study. The age of patients was from 18 to 65 years. The patients underwent standard examinations, as well as immunological studies, before administration of the anti-relapse treatment, and 12 months after the treatment was started. Immunological testing included immunophenotyping of lymphocytes with counting of T and B lymphocytes, immunoregulatory and activated subpopulations of T lymphocytes, determination of urinary immunoglobulins (IgM, IgG, IgA) by immunoturbidimetric assays, proinflammatory cytokines – IL-1β, IL-8, IL-17A and anti-inflammatory cytokine IL-10 by ELISA tests. As a result of studies, the examined patients showed an increased contents of T helper cells, activated T lymphocytes (CD8+HLA-DR+CD45+, CD3+CD8brightCD38+) along with decreased numbers of Treg cells and an increased contents of proinflammatory cytokines IL-1β, IL-8, IL-17A and immunoglobulins of all three classes in urinary samples.The cohort of patients with GN selected for the study was divided in two groups (the main group and the comparison group). In addition to nephroprotective and steroid therapy, the treatment regimen of patients included rIL-2 in the main group, or cyclophosphamide in the comparison group. Regardless of the method used, the levels of protein, IgG and IL-17A in the urine proved to be decreased relative to the initial values; the contents of B cells and HLA-DR+ cytotoxic T lymphocytes in peripheral blood were found to be decreased. The revealed changes were more pronounced in the main group of patients. By 12 months after starting the treatment, the mentioned indexes began to differ significantly in the main group from those in the comparison group. Serum creatinine levels, numbers of T helper cells and Treg cells, IL-1β levels in urine did not undergo significant changes in the comparison group, whereas a decrease in serum creatinine and urinary IL-1β was registered in the main group of patients, along with decreased number of T helpers and increased numbers of Treg cells. In the main group of patients treated with rIL-2, the average number of relapses per year decreased by 4 times, showing only a 1.2-fold decrease in the comparison group. Hence, the low-dose therapy with rIL-2 may be considered an effective and safe alternative to conventional immunosuppressive therapy and a new option of the targeted treatment of glomerulonephritis with frequent recurrence of nephrotic syndrome.
first_indexed 2024-03-08T05:46:57Z
format Article
id doaj.art-b9bc3e35690f4a99865041bcc4fb45b9
institution Directory Open Access Journal
issn 1563-0625
2313-741X
language Russian
last_indexed 2024-04-24T06:49:09Z
publishDate 2024-01-01
publisher St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists
record_format Article
series Медицинская иммунология
spelling doaj.art-b9bc3e35690f4a99865041bcc4fb45b92024-04-22T13:07:51ZrusSt. Petersburg branch of the Russian Association of Allergologists and Clinical ImmunologistsМедицинская иммунология1563-06252313-741X2024-01-0126118119010.15789/1563-0625-ANA-26701793A new approach to immunosuppressive therapy in patients with glomerulonephritis with nephrotic syndromeS. I. Kudryashov0M. A. Stenina1L. M. Karzakova2T. S. Lutkova3I. Ulianov Chuvash State UniversityN. Pirogov Russian National Research Medical UniversityI. Ulianov Chuvash State UniversityI. Ulianov Chuvash State UniversityGlomerulonephritis (GN) is a group of immuno-inflammatory kidney diseases with predominant glomerular lesions that are difficult to treat. The greatest problems are caused by the treatment of GN with nephrotic syndrome, which often has a recurrent course. The aim of the research was to study the effectiveness of recombinant interleukin-2 (rIL-2) therapy in the GN patients with nephrotic syndrome. 62 patients with a nephrotic form of primary GN with frequent relapses admitted to the Nephrology Department have been recruited into the study. The age of patients was from 18 to 65 years. The patients underwent standard examinations, as well as immunological studies, before administration of the anti-relapse treatment, and 12 months after the treatment was started. Immunological testing included immunophenotyping of lymphocytes with counting of T and B lymphocytes, immunoregulatory and activated subpopulations of T lymphocytes, determination of urinary immunoglobulins (IgM, IgG, IgA) by immunoturbidimetric assays, proinflammatory cytokines – IL-1β, IL-8, IL-17A and anti-inflammatory cytokine IL-10 by ELISA tests. As a result of studies, the examined patients showed an increased contents of T helper cells, activated T lymphocytes (CD8+HLA-DR+CD45+, CD3+CD8brightCD38+) along with decreased numbers of Treg cells and an increased contents of proinflammatory cytokines IL-1β, IL-8, IL-17A and immunoglobulins of all three classes in urinary samples.The cohort of patients with GN selected for the study was divided in two groups (the main group and the comparison group). In addition to nephroprotective and steroid therapy, the treatment regimen of patients included rIL-2 in the main group, or cyclophosphamide in the comparison group. Regardless of the method used, the levels of protein, IgG and IL-17A in the urine proved to be decreased relative to the initial values; the contents of B cells and HLA-DR+ cytotoxic T lymphocytes in peripheral blood were found to be decreased. The revealed changes were more pronounced in the main group of patients. By 12 months after starting the treatment, the mentioned indexes began to differ significantly in the main group from those in the comparison group. Serum creatinine levels, numbers of T helper cells and Treg cells, IL-1β levels in urine did not undergo significant changes in the comparison group, whereas a decrease in serum creatinine and urinary IL-1β was registered in the main group of patients, along with decreased number of T helpers and increased numbers of Treg cells. In the main group of patients treated with rIL-2, the average number of relapses per year decreased by 4 times, showing only a 1.2-fold decrease in the comparison group. Hence, the low-dose therapy with rIL-2 may be considered an effective and safe alternative to conventional immunosuppressive therapy and a new option of the targeted treatment of glomerulonephritis with frequent recurrence of nephrotic syndrome.https://www.mimmun.ru/mimmun/article/view/2670immunosuppressionglomerulonephritisrecombinant interleukin-2nephrotic syndrometreg cellstreatment of glomerulonephritis
spellingShingle S. I. Kudryashov
M. A. Stenina
L. M. Karzakova
T. S. Lutkova
A new approach to immunosuppressive therapy in patients with glomerulonephritis with nephrotic syndrome
Медицинская иммунология
immunosuppression
glomerulonephritis
recombinant interleukin-2
nephrotic syndrome
treg cells
treatment of glomerulonephritis
title A new approach to immunosuppressive therapy in patients with glomerulonephritis with nephrotic syndrome
title_full A new approach to immunosuppressive therapy in patients with glomerulonephritis with nephrotic syndrome
title_fullStr A new approach to immunosuppressive therapy in patients with glomerulonephritis with nephrotic syndrome
title_full_unstemmed A new approach to immunosuppressive therapy in patients with glomerulonephritis with nephrotic syndrome
title_short A new approach to immunosuppressive therapy in patients with glomerulonephritis with nephrotic syndrome
title_sort new approach to immunosuppressive therapy in patients with glomerulonephritis with nephrotic syndrome
topic immunosuppression
glomerulonephritis
recombinant interleukin-2
nephrotic syndrome
treg cells
treatment of glomerulonephritis
url https://www.mimmun.ru/mimmun/article/view/2670
work_keys_str_mv AT sikudryashov anewapproachtoimmunosuppressivetherapyinpatientswithglomerulonephritiswithnephroticsyndrome
AT mastenina anewapproachtoimmunosuppressivetherapyinpatientswithglomerulonephritiswithnephroticsyndrome
AT lmkarzakova anewapproachtoimmunosuppressivetherapyinpatientswithglomerulonephritiswithnephroticsyndrome
AT tslutkova anewapproachtoimmunosuppressivetherapyinpatientswithglomerulonephritiswithnephroticsyndrome
AT sikudryashov newapproachtoimmunosuppressivetherapyinpatientswithglomerulonephritiswithnephroticsyndrome
AT mastenina newapproachtoimmunosuppressivetherapyinpatientswithglomerulonephritiswithnephroticsyndrome
AT lmkarzakova newapproachtoimmunosuppressivetherapyinpatientswithglomerulonephritiswithnephroticsyndrome
AT tslutkova newapproachtoimmunosuppressivetherapyinpatientswithglomerulonephritiswithnephroticsyndrome